相关实验视频
Updated: Jun 29, 2025

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.0K
代谢综合征对扩散大B细胞淋巴瘤预后的影响
Wenjing Xiong1, Liru Li1, Xue Hui1
1Department of Clinical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China.
概括
代谢综合征 (MetS) 与扩散性大B细胞淋巴瘤 (DLBCL) 患者的治疗结果较差有关. 治疗前的MetS,以及IPI得分和rituximab使用,独立地预测了更糟糕的预后.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 代谢疾病 代谢疾病
背景情况:
- 代谢综合征 (MetS) 与癌症预后有关,但其在扩散性大B细胞淋巴瘤 (DLBCL) 中的作用尚不清楚.
- 了解影响DLBCL预后的因素对于患者的治疗结果至关重要.
研究的目的:
- 调查MetS和临床病理学变量对DLBCL预后的影响.
- 为了确定DLBCL患者的独立预后因素.
主要方法:
- 从319名DLBCL患者 (2012-2020) 的临床和病理数据的回顾性分析.
- 使用SPSS进行统计分析,包括t测试和单变量/多变量COX回归.
主要成果:
- MetS存在与较差的整体存活率 (OS) 和无进展存活率 (PFS) 相相关.
- 对于DLBCL预后的独立风险因素包括MetS,IPI得分,Ki-67表达和rituximab使用.
- 年龄,瘤阶段和乳酸脱酶水平也与生存有关.
结论:
- 在DLBCL患者中,治疗前的MetS与显著缩短的OS和PFS有关.
- 在DLBCL中,MetS是独立的负预后因素,与IPI得分,Ki-67和Rituximab一起.
- 这些发现强调了MetS作为DLBCL管理的关键因素.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K

